<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT932-1748</title>
	</head>
	<body>
		<main>
			<p>930622 FT  22 JUN 93 / London Stock Exchange: Wellcome fears The worst individual performance in the FT-SE 100 Index came from Wellcome, whose shares fell 3.4 per cent after being hit by a series of bearish developments. These included the cancellation of a clinical study of one of its drugs, Flolan, which dragged down a share price already burdened by worries about litigation over Wellcome's Aids drug Retrovir and press comment detailing criticism of Wellcome's herpes drug Zovirax. Another factor helping to depress the shares was a downgrading of the drugs sector by Kidder Peabody, one of the leading US brokerages, last Friday night. Wellcome shares dropped to 702p at one point before stabilising and closing a net 25 down at 705p, the lowest closing level since April 19. Turnover of 4.6m was well above usual levels of activity. Commenting on the barrage of bad news, one leading analyst said: 'The Flolan news is unhelpful but not particularly bad, while there is nothing new in the other stories.'</p>
		</main>
</body></html>
            